Alan Kelly, MD
Internal Medicine · Spokane Valley, WANPI 1306834833
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,866 of the $96,179 with a category attached, or 76.8%. 14 manufacturers reported payments, led by Lilly USA, LLC at 52.1% of the total. Reporting peaked in 2019 at $72,238 and has fallen 99.7% since, to $182 in 2025. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $460.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$50K
- Novo Nordisk$32K
- Boehringer Ingelheim$11K
- Abbott$1K
- Medtronic$563
- AstraZeneca$430
- plus $558 from 8 others
What the payments were for
- Consulting fees$6,1756%
- Speaking & faculty fees$73,86677%
- Travel & lodging$11,25812%
- Food & beverage$4,7575%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 105 | $50,129 |
| Novo Nordisk | 33 | $31,750 |
| Boehringer Ingelheim | 23 | $11,348 |
| Abbott | 7 | $1,400 |
| Medtronic(2 entities) | 10 | $563 |
| AstraZeneca | 21 | $430 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Inspire Medical Systems, Inc. | 1 | $122 |
| Amgen | 1 | $65 |
| Pfizer | 2 | $46 |
| Dexcom, Inc. | 2 | $45 |
| GSK | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$31,083
- JARDIANCE$25,950
- Ozempic$13,611
- Tresiba$11,669
- Xultophy 100/3.6$2,633
- RYBELSUS$2,525
- FreeStyle Libre Pro$1,050
- MINIMED 780G$407
- FREESTYLE LIBRE 3$140
- TRINTELLIX$125
- Inspire Upper Airway Stimulation System$122
- FARXIGA$105
How this compares
$96,179 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 142 | $242,821 |
| JardianceEmpagliflozin | 187 | $218,665 |
| OzempicSemaglutide | 101 | $154,541 |
| XareltoRivaroxaban | 78 | $76,696 |
| MounjaroTirzepatide | 50 | $65,221 |
| Tresiba Flextouch U-200Insulin Degludec | 84 | $58,280 |
| FarxigaDapagliflozin Propanediol | 54 | $57,740 |
| MyrbetriqMirabegron | 60 | $46,612 |
| EliquisApixaban | 32 | $38,434 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $15,692 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $15,477 |
| LinzessLinaclotide | 13 | $15,451 |
| Rosuvastatin Calcium | 829 | $13,864 |
| Bydureon BciseExenatide Microspheres | 15 | $12,674 |
| JanuviaSitagliptin Phosphate | 21 | $12,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $50,129 | $308,043192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $11,348 | $226,627199 claims |
| Novo NordiskOzempic | $31,750 | $154,541101 claims |
| Johnson & JohnsonXarelto | $13 | $76,69678 claims |
| AstraZenecaFarxiga, Symbicort | $430 | $62,46265 claims |
| PfizerEliquis, Premarin | $46 | $43,85149 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $18 | $25,67532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Spokane Valley
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
- Safoora ZakaPort Orchard$67K
- Tianna TsitsisBurlington$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.